Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Livedoid Vasculopathy

ClinicalTrials.gov lists 84 trials for Livedoid Vasculopathy or a narrower condition beneath it. MediQuest Therapeutics has the most among industry and government lead sponsors, with 8.

MeSH D000090122 Cardiovascular Diseases C14 C17 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 5 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 17 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 15 Phase 4 Phase 4 6 Not applicable Not applicable 21 Observational Observational 14 Phase 1 Phase 1 5 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 17 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 15 Phase 4 Phase 4 6 Not applicable Not applicable 21 Observational Observational 14

Trials per phase (log scale)

2 of the 84 trials are tagged with Livedoid Vasculopathy itself; the rest are tagged with a narrower condition beneath it.

Get the Livedoid Vasculopathy report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Livedoid Vasculopathy trials start? (25)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 7

1992: 1 trials (Phase 3 1) 1995: 1 trials (Phase 3 1) 2001: 3 trials (Phase 4 2, Phase 2 1) 2004: 2 trials (Not applicable 1, Phase 2/3 1) 2005: 2 trials (Phase 3 1, Phase 2 1) 2006: 3 trials (Phase 3 1, Phase 2/3 1, Phase 2 1) 2007: 7 trials (Observational 1, Phase 3 4, Phase 2 2) 2008: 2 trials (Not applicable 1, Phase 1 1) 2009: 3 trials (Phase 3 2, Phase 1 1) 2010: 2 trials (Not applicable 1, Phase 2 1) 2011: 5 trials (Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 2) 2012: 1 trials (Not applicable 1) 2013: 3 trials (Observational 1, Phase 2/3 1, Phase 2 1) 2014: 6 trials (Observational 1, Not applicable 2, Phase 2/3 1, Phase 2 2) 2015: 7 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2 1, Phase 1/2 1) 2016: 5 trials (Not applicable 3, Phase 1 2) 2017: 2 trials (Not applicable 2) 2018: 4 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1) 2019: 5 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 1) 2020: 6 trials (Observational 2, Not applicable 2, Phase 2 1, Phase 1 1) 2021: 3 trials (Observational 2, Phase 2 1) 2022: 4 trials (Not applicable 2, Phase 4 1, Phase 2 1) 2023: 2 trials (Observational 2) 2025: 2 trials (Not applicable 1, Phase 4 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2
2025 2
2023 2
2022 4
2021 3
2020 6
2019 5
2018 4
2017 2
2016 5

Showing 10 of 25 earlier years.

Start your 14-day trial Email me all 25 earlier years as a PDF

No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Livedoid Vasculopathy trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 5
Phase 1/2 1
Phase 2 17
Phase 2/3 5
Phase 3 15
Phase 4 6
Not applicable 21
Observational 14

How many Livedoid Vasculopathy trials are recruiting? (6)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 3
Recruiting 3
Completed 55
Terminated 7
Withdrawn 4

Showing 5 of 6 statuses.

Start your 14-day trial Email me all 6 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Livedoid Vasculopathy trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
MediQuest Therapeutics 8
Civi Biopharma, Inc. 2
Otsuka America Pharmaceutical 2
Pfizer 2
Sanjay Gandhi Postgraduate Institute of Medical Sciences 2

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Livedoid Vasculopathy? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Nitroglycerin 4
SILDENAFIL 2
Cilostazol 2
Botulinum Toxin 2

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Tadalafil Pill 4
type A botulinum toxin 3
Iloprost Injection, for intravenous use 2
Topical organogel with nitroglycerin 2
Sham device 2

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Livedoid Vasculopathy trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Infection 3 1
Broken bone 1 1
Collapsed Lung 1 1
Dizziness 1 1
Facial edema 1 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Livedoid vasculopathy Annual incidence 1-9 / 100 000 United States US Unspecified
Livedoid vasculopathy Annual incidence 1-9 / 100 000 United States US Exact
Livedoid vasculopathy Annual incidence 1-9 / 100 000 United States US Exact
Livedoid vasculopathy Point prevalence Unknown Worldwide Not stated Unspecified
Livedoid vasculopathy Point prevalence Unknown Worldwide Not stated Exact

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Livedoid vasculopathy 542643 Exact Orphanet Rare Disease Ontology (ORDO)
Livedoid vasculopathy 542643 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications.

Browse all condition evidence pages